Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Hypertension. 2012 Feb 6;59(3):719–725. doi: 10.1161/HYPERTENSIONAHA.111.181404

Figure 1.

Figure 1

Comparison of serum TxB2 levels between patients with and without metabolic syndrome (P=0.013), all of whom had known coronary artery disease. The dashed line (13 ng/mL) represents an estimate of 95% inhibition of cyclooxygenase.